Trial Profile
A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Behcet's syndrome; Posterior uveitis
- Focus Therapeutic Use
- 20 Jul 2011 New trial record